Novo Nordisk has announced the establishment of a new program aimed at providing access to Wegovy (injectable semaglutide) within Brazil's public health system, known as the Sistema Único de Saúde (SUS). This initiative is part of a broader effort to treat severe obesity and will be implemented at selected public health centers across the country. The program is intended to generate valuable data on the efficacy and implementation of obesity treatments within the public sector.

Initially, the program will roll out in three specific public health centers: one in Porto Alegre (RS) through the Grupo Hospitalar Conceição (GHC), another at the Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione (IEDE) in Rio de Janeiro, and a third center that will be determined later. Patients who are already receiving care at these institutions will be the primary beneficiaries, though each facility will set its own eligibility criteria based on local healthcare protocols and conditions.

This initiative, planned to last for two years, marks a significant step in providing new treatment options for obesity within Brazil’s public health framework, where currently there are no approved medications available for this condition. By focusing on obesity treatment, Novo Nordisk aims to tackle a growing health issue in Brazil and assist in improving patient outcomes through better access to necessary medications.